Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Siang-Boon Koh; Leif W Ellisen

doi:10.1016/j.ccell.2021.11.001

Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer

Cancer Cell. 2021 Dec 13;39(12):1562-1564. doi: 10.1016/j.ccell.2021.11.001. Epub 2021 Nov 11.

Authors

Siang-Boon Koh¹, Leif W Ellisen²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
² Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA. Electronic address: lellisen@mgh.harvard.edu.

PMID: 34767761
DOI: 10.1016/j.ccell.2021.11.001

Abstract

Immune checkpoint blockade plus chemotherapy is emerging as a standard treatment for some patients with triple-negative breast cancer (TNBC). In this issue of Cancer Cell, Zhang et al. employ extensive single-cell immune compartment analyses of pre- and post-therapy TNBC, and they reveal potential mechanisms of T cell activation and patterns of immune evolution that may inform future biomarkers of response and clinical benefit.

Publication types

Comment

MeSH terms

Humans
Triple Negative Breast Neoplasms* / drug therapy
Triple Negative Breast Neoplasms* / genetics